EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY 4.0

Resistance Analysis of Low-Level Virologic Rebound During HIV-1 Treatment With Lenacapavir and Broadly Neutralizing Antibodies Teropavimab and Zinlirvimab

Lisa Selzer, Sally Demirdjian iD, Brie Falkard iD, Jiani Li iD, Ross Martin iD, Sean E Collins, Joseph Eron, Laurie A VanderVeen, Christian Callebaut

The Journal of Infectious Diseases · 17.01.2026 · 233 (1) · e212-e220

DOI: 10.1093/infdis/jiaf559 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift The Journal of Infectious Diseases, online erschienen am 05.11.2025. Verfasst von Lisa Selzer und 8 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Virology, Gilead Sciences, Inc., Foster City, California, USA. Hauptthemen laut MEDLINE: HIV-1, HIV Infections, Drug Resistance, Viral, Anti-HIV Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gilead Sciences, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

High rates of virologic suppression were observed in the Phase 1b study (NCT04811040) investigating lenacapavir and two broadly neutralizing antibodies (bNAb), teropavimab (30 mg/kg) and zinlirvimab (10 or 30 mg/kg), in virologically suppressed people with HIV-1 susceptible (IC90 ≤ 2 μg/mL) to both (primary cohort, n = 20) or either (pilot cohort, n = 10) bNAb. We describe resistance analyses through Week (W) 26.

Methods

Post-baseline resistance analyses were conducted at virologic failure, and exploratory resistance analyses performed for participants with virologic rebound. Low copy number genotyping methods for capsid and a 1 kb stretch of gp120 from rebound virus were developed, and phenotypic susceptibility assessed.

Results

Virologic failure was observed in 1/30 participants. This primary cohort participant had HIV RNA 155 copies/mL at W16 and developed Q67H in capsid (lenacapavir fold-change 4.7), without resistance to bNAbs; the participant resuppressed on oral antiretrovirals. Two pilot cohort participants, experienced virologic rebound at W26 (55 and 72 copies/mL) and restarted oral antiretrovirals. In exploratory analyses, neither had emergent lenacapavir resistance or altered bNAb susceptibility.

Conclusions

Lenacapavir, teropavimab, and zinlirvimab maintained a high rate of virologic suppression through W26, with rare emergent lenacapavir resistance and no bNAb resistance, supporting further Phase 2 evaluation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV-1HIV InfectionsDrug Resistance, ViralAnti-HIV AgentsAntibodies, NeutralizingBroadly Neutralizing AntibodiesAntibodies, Monoclonal, HumanizedHumansMaleFemaleAdultViral LoadMiddle AgedAcetamidesIndazoles

Stichwörter der Autor:innen

HIVlenacapavirresistanceteropavimabzinlirvimab

Substanzen

Anti-HIV AgentsAntibodies, NeutralizingBroadly Neutralizing AntibodiesAntibodies, Monoclonal, HumanizedlenacapavirAcetamidesIndazoles

Autor:innen und Institutionen

  • Clinical Virology, Gilead Sciences, Inc., Foster City, California, USA.
  • Bioinformatics, Gilead Sciences, Inc., Foster City, California, USA.
  • Clinical Development, Gilead Sciences, Inc., Foster City, California, USA.
  • Division of Infectious Diseases, University of North Carolina, Chapel Hill, North Carolina, USA.

ORCID-Profile: Sally Demirdjian, Brie Falkard, Jiani Li, Ross Martin

Förderung

  • Gilead Sciences, Inc.

Zitieren

APA

Selzer, L., Demirdjian, S., Falkard, B., Li, J., Martin, R., Collins, S. E., Eron, J., VanderVeen, L. A., & Callebaut, C. (2026). Resistance Analysis of Low-Level Virologic Rebound During HIV-1 Treatment With Lenacapavir and Broadly Neutralizing Antibodies Teropavimab and Zinlirvimab. The Journal of Infectious Diseases, 233(1), e212-e220. https://doi.org/10.1093/infdis/jiaf559

Vancouver

Selzer L, Demirdjian S, Falkard B, Li J, Martin R, Collins SE, et al. Resistance Analysis of Low-Level Virologic Rebound During HIV-1 Treatment With Lenacapavir and Broadly Neutralizing Antibodies Teropavimab and Zinlirvimab. The Journal of Infectious Diseases. 2026;233(1):e212-e220. doi:10.1093/infdis/jiaf559

BibTeX
@article{Selzer2026,
  author = {Selzer, Lisa and Demirdjian, Sally and Falkard, Brie and Li, Jiani and Martin, Ross and Collins, Sean E and Eron, Joseph and VanderVeen, Laurie A and Callebaut, Christian},
  title = {Resistance Analysis of Low-Level Virologic Rebound During HIV-1 Treatment With Lenacapavir and Broadly Neutralizing Antibodies Teropavimab and Zinlirvimab},
  journal = {The Journal of Infectious Diseases},
  year = {2026},
  volume = {233},
  number = {1},
  pages = {e212--e220},
  doi = {10.1093/infdis/jiaf559}
}
Kostenlos starten →